GLPwatch
Papers (10389)
Page 160 of 174, ranked by citation count.
- Interplay of childhood metabolic dysfunction-associated steatotic liver disease and obesity in the development of youth-onset type 2 diabetes.
- Association Between GLP-1 Receptor Agonists and the Risk of Colon Cancer in Adults With Type 2 Diabetes or Obesity: A Systematic Review and Network Meta-Analysis.
- Peptide Mapping Using Multienzyme Digestion Strategies Integrated with LC-HRMS Workflow: A Case Study.
- Methodological and statistical inconsistencies compromise the efficacy and safety analyses of orforglipron.
- Influence of Social Media on Self-Medication Behavior: A Study on Ozempic Use Among Emirati University Students.
- Liraglutide versus colesevelam for treating bile acid diarrhoea.
- Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives.
- Shifts in waist-to-height ratio categories within tirzepatide groups: a post-hoc analysis of SURMOUNT-1.
- Therapeutic potential of targeting ceramide for early cardiometabolic lipotoxicity in vivo study.
- Mediterranean diet adherence and tirzepatide: real-world evidence on adiposity indices and insulin resistance beyond weight loss.
- GLP-1 receptor agonists, SGLT-2 inhibitors, and their combination: effects on carotid atherosclerosis regression, oxidative stress, and amyloid-β1-40 in diabetes.
- Efficacy and Safety of Oral GLP-1 RA Orforglipron on Weight and Glycemic Control According to Diabetes Status: A Systematic Review and Meta-Analysis.
- Predicting Weight Outcomes From Obesity Medications in a Paediatric Population.
- LiCl-driven direct synthesis of mono-protected esters from long-chain dicarboxylic fatty acids.
- The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial.
- Insights into semaglutide cardiovascular research: Mechanisms, trials, and frontiers.
- Combination of prolonged water fasting and GLP-1 for refractory morbid obesity: Case report.
- Once-Weekly Mazdutide in Obesity or Overweight.
- To Reenvision and Redefine: Considering the Role of Lifestyle Interventions in the New Era of Second-Generation Obesity Management Medications.
- Euglycemic diabetic ketoacidosis following treatment with tirzepatide and SGLT-2 inhibitors: A case report and literature review.
- Glucagon-Like Peptide-1 Receptor Agonists in Managing High Stoma Output: A Scoping Review.
- Are Glucagon-Like Peptide 1 Receptor Agonists and Bariatric Surgery the Answer to Childhood Obesity?
- Semaglutide, at a dose that produces modest weight loss, induces mild suppression of bone remodeling in healthy control rats and those with chronic kidney disease.
- Effect of Tirzepatide on Cardiovascular Outcomes.
- Glucagon-like peptide-1 receptor agonist use and clinical outcomes after posterior cervical spinal fusion for degenerative pathologies: A large cohort retrospective analysis.
- Variable Effects of Glucagon Like Peptide-1 Receptor Agonists on Body Composition in Older Women.
- Development of an electrochemiluminescence immunoassay for quantitative determination of semaglutide in human serum.
- Evaluation of the safety profile of glucagon-like peptide-1 receptor agonists: a focus on thyroid cancer-related adverse events by using the European pharmacovigilance database.
- Real-World Cardiovascular Outcomes of GLP-1 Receptor Agonists in Women With Type 2 Diabetes and Breast Cancer.
- [Diabetes Mellitus Type 2: Recent Publications and New Drugs].
- [SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?]
- Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.
- Assessing the Oncological Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review and Meta-Analysis.
- Comparison of low-dose liraglutide use versus other GLP-1 receptor agonists in patients without type 2 diabetes.
- Unanticipated Adverse Events With Tirzepatide: Three Cases Underscoring the Importance of Postmarketing Monitoring.
- Revitalizing GIP: Therapeutic Potential in Metabolic and Neurodegenerative Disorders.
- Efficacy of dulaglutide after switching from incretin-related drugs in patients with type 2 diabetes and inadequate glycemic control.
- Reducing Periprosthetic Joint Infection in Patients With Obesity: A Systematic Review and Meta-Analysis of the Emerging Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists.
- The role of combination therapy in type 2 diabetes in the post-ACCORD era.
- Pre-Treatment Concerns and Their Association With Functioning and Well-Being During Incretin-Based Therapy: A Cross-Sectional Study.
- Glucagon-Like Peptide-1 Agonist vs. Placebo and Pulmonary Decline After Open-Heart Surgery: A Substudy of the GLORIOUS Randomised Clinical Trial.
- Multidimensional Predictors of Tirzepatide Efficacy: Clinical, Genetic, and Molecular Biomarkers for Glycemic, Weight, and Organ Protection.
- Tirzepatide ameliorates type 2 diabetes-associated male reproductive dysfunction via modulation of the Nrf2/Keap1 pathway.
- Managing post-bariatric hypoglycemia: a systematic review of pharmacological therapies.
- An analysis of dosage volume for halfway doses in the Victoza Pen.
- Tirzepatide - A major breakthrough in the fight against obesity.
- Assessment of the Potential of GLP-1 Analogs in the Treatment of Addictions: A Literature Review.
- Comparative effects of pharmacological treatment for weight gain in patients treated with antipsychotics. A systematic review and network meta-analysis.
- Short-Term Associations Between Fat-Free Mass Preservation and Glycaemic Markers During Tirzepatide Therapy: A Secondary Exploratory Analysis.
- [Cardiovascular protection of patients with type 2 diabetes : from EMPA-REG OUTCOME to LEADER].
- Assessment of Thermal and Photolytic Stress Effects on the Stability of Primary Structure of Synthetic Liraglutide Using LC-HRMS/MS.
- [Nutritional management of type 2 diabetes with GLP-1 and GLP-1/GIP agonists].
- GLP-1 Agonist Attenuates Nicotine Reward-Related Behavior by Regulating the Prepro-Orexin in the Hypothalamus and Prepro-Glucagon in the Nucleus Tractus Solitarius.
- Tirzepatide mitigates thoracic aortic aneurysm and dissection by alleviating the loss of the contractile phenotype in vascular smooth muscle cells and reducing vascular inflammation.
- Glucagon-Like Peptide-1 Receptor Agonists Across the Heart Failure Spectrum: A Systematic Review and Meta-Analysis.
- A Fluorescent Probe-Based Platform for Precise Pharmaceutical Analysis and Quality Assessment of Tirzepatide.
- Prevalence of Obesity Medications in the Military Health System: An Update from 2022.
- Mazdutide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Endoplasmic Reticulum Stress, Improving Lipid Metabolism and Alleviating Inflammation.
- Do GLP-1 Receptor Agonists Sabotage Fat Grafts? : A Scoping Review of GLP-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat Transfer.
- Risk factors for drug-related impaired gastric emptying: a pharmacovigilance analysis of the FDA adverse event reporting system.